GSK256066 (Trifluoroacetate)
Selected Variant
HY-70069-01
Size: 5 mg
GSK256066 Trifluoroacetate is a selective and high-affinity phosphodiesterase 4 (PDE) inhibitor, with an IC50 of 3.2 pM for PDE4B. GSK256066 Trifluoroacetate is developed for the research of chronic obstructive pulmonary disease[1].
Product Specifications
CAS Number
1415560-64-3
UNSPSC
12352005
Target
Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/GSK256066-2,2,2-trifluoroacetic-acid.html
Concentration
10mM
Purity
99.83
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
OC(C(F)(F)F)=O.O=C(N)C1=C(C2=CC(S(=O)(C3=CC=CC(C(N(C)C)=O)=C3)=O)=CC(C)=C2N=C1)NC4=CC=CC(OC)=C4
Molecular Formula
C29H27F3N4O7S
Molecular Weight
632.61
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PDE4
Available Sizes
Price
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
P21 / WAF1 (WA-1), CF740 conjugate, 0.1mg/mL
Ep-CAM / CD326 (Epithelial Marker) (rVU-1D9), CF740 conjugate, 0.1mg/mL
Ep-CAM / CD326 (VU-1D9), CF555 conjugate, 0.1mg/mL
